Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples